NCT00337077已完成2 期
A Phase II Trial of E7389 (Halichondrin B Analog), in Patients With Metastatic Hormone Refractory Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 121
- 试验地点
- 146
- 主要终点
- Proportion of Patients With PSA Response
研究概览
简要总结
This phase II trial is studying how well eribulin mesylate (E7389; Halichondrin B Analog) works in treating patients with metastatic prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
详细描述
PRIMARY OBJECTIVES:
I. Determine the number of patients with a > 50% decrease in prostate-specific antigen (PSA) of at least 4 weeks duration in patients with hormone-refractory metastatic prostate cancer treated with E7389 (eribulin mesylate).
SECONDARY OBJECTIVES:
I. Estimate the measurable disease response in patients with measurable disease.
II. Determine the duration of PSA and measurable disease response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed adenocarcinoma of the prostate
- •Progressive metastatic disease or stable metastatic disease with rising PSA
- •Previously treated with bilateral orchiectomy or other primary hormonal therapy with evidence of treatment failure
- •Patients who have not undergone bilateral orchiectomy must continue luteinizing hormone-releasing hormone (LHRH)-agonist therapy (e.g., leuprolide or goserelin) or LHRH antagonist therapy (e.g. abarelix) while receiving study treatment
- •Patients who did not have an orchiectomy must have a testosterone level < 50 ng/dL to confirm androgen suppression within the past 4 weeks
- •ECOG performance status 0-2
- •Adequate bone marrow function
- •Bilirubin =< 1.5 mg/dL
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
- •Creatinine =< 2.0 mg/dL OR creatinine clearance >= 40 mL/min
- •Fertile patients must use effective contraception
- •A taxane-based regimen, mitoxantrone, or other cytotoxic chemotherapy regimen allowed provided there is evidence of disease progression
- •At least 4 weeks since prior chemotherapy or radiotherapy
- •At least 4 weeks since prior flutamide (6 weeks for bicalutamide or nilutamide) and there is continued evidence of disease progression
- •Disease progression after antiandrogen withdrawal must be confirmed by rising PSA after the required 4-6 week washout period (e.g., PSA level higher than the last PSA obtained while on antiandrogen therapy)
- •More than 4 weeks since prior estrogen, estrogen-like agents (e.g., PC-SPES, saw palmetto, or other herbal products that may contain phytoestrogens), or any other hormonal therapy (including megestrol, finasteride, ketoconazole, or systemic corticosteroids)
- •Concurrent bisphosphonates (e.g., pamidronate sodium or zoledronate) allowed provided the patient has been receiving the bisphosphonate for >= 4 weeks and there is evidence of disease progression
排除标准
- •Active angina pectoris
- •Known New York Heart Association class III-IV heart disease
- •Myocardial infarction within the past 6 months
- •Evidence of ventricular dysrhythmias or other unstable arrhythmia (rate-controlled atrial fibrillation is allowed if the patient is asymptomatic from a cardiac standpoint)
- •Peripheral neuropathy > grade 2
- •Other prior malignancy (excluding nonmelanomatous skin cancer treated with curative intent) unless the malignancy was treated with curative intent and the patient has been disease free for >= 5 years
- •Serious concurrent medical illness or active infection that would preclude study treatment - No concurrent strong inhibitors or inducers of CYP3A4
- •More than 2 prior chemotherapy regimens for hormone-refractory disease - Other concurrent investigational agents
- •Other concurrent anticancer therapy, including chemotherapy, gene therapy, biologic therapy, or immunotherapy
- •Concurrent palliative radiotherapy
- •Concurrent estrogen, estrogen-like agents, or any other hormonal therapy
- •Carcinomatous meningitis or brain metastases
- •Prior strontium chloride Sr 89, samarium 153 lexidronam pentasodium, or other radioisotopes
- •Concurrent therapeutic anticoagulation with warfarin (Unfractionated heparin [standard, low-dose, or adjusted dose] or low molecular weight heparin allowed
研究组 & 干预措施
Eribulin mesylate
Experimental
Patients receive eribulin mesylate IV over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
干预措施: eribulin mesylate (Drug)
结局指标
主要结局
Proportion of Patients With PSA Response
时间窗: Assessed every 3 weeks during treatment; after off-treatment, every 3 months if patient is <2 years from study entry and every 6 months if patient is 2-5 years
PSA response is defined as a PSA decline from baseline value by \>=50%, or normalization of PSA (\<0.2 ng/ml) confirmed by a second measurement greater than or equal to 4 weeks later.
次要结局
- Proportion of Patients With Measurable Disease Response(Assessed every 9 weeks during treatment; after off-treatment, every 3 months if patient is <2 years from study entry and every 6 months if patient is 2-5 years from study entry)
研究者
研究点 (146)
Loading locations...
相似试验
进行中（未招募）
1 期
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney DysfunctionAdvanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaRecurrent Urothelial CarcinomaStage III Bladder Urothelial Carcinoma AJCC v6 and v7Stage IV Bladder Urothelial Carcinoma AJCC v7Unresectable Urothelial CarcinomaNCT00365157National Cancer Institute (NCI)171
已完成
2 期
E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT00400829National Cancer Institute (NCI)66
已完成
2 期
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer PatientsAdenocarcinoma of the PancreasRecurrent Pancreatic CancerStage II Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic CancerPancreatic CancerNCT00383760National Cancer Institute (NCI)15
已完成
1 期
Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by SurgeryAdult Solid NeoplasmRecurrent Ovarian CarcinomaRecurrent Uterine Corpus CarcinomaStage III Ovarian Cancer AJCC v6 and v7Stage III Uterine Corpus Cancer AJCC v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Uterine Corpus Cancer AJCC v7NCT00410553National Cancer Institute (NCI)45
已完成
2 期
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerNCT00334893National Cancer Institute (NCI)74